Lehman Brothers UK Capital Funding LP
LONDON, March 17, 2021 (GLOBE NEWSWIRE) --
NOTICE TO THE HOLDERS OF:
EUR 225,000,000 FIXED RATE TO CMS-LINKED GUARANTEED NON-VOTING, NON-CUMULATIVE PERPETUAL PREFERRED SECURITIES ("LP I Securities")
ISSUER: LEHMAN BROTHERS UK CAPITAL FUNDING LP ("LP I")
ISIN: XS0215349357
LIQUIDATION OF LB GP NO.1 LTD ("the Company") AND IMPLICATIONS FOR HOLDERS OF LP I SECURITIES
THIS NOTICE CONTAINS IMPORTANT INFORMATION THAT IS OF INTEREST TO THE REGISTERED AND BENEFICIAL OWNERS OF THE SUBJECT SECURITIES. IF APPLICABLE, ALL DEPOSITORIES, CUSTODIANS AND OTHER INTERMEDIARIES RECEIVING THIS NOTICE ARE REQUESTED TO EXPEDITE THE RE-TRANSMITTAL TO BENEFICIAL OWNERS OF THE SECURITIES IN A TIMELY MANNER.
Your attention is drawn to the formal notice contained in the PDF link below concerning the Company, LP I and the LP I Securities. In order to view the formal notice, it is recommended that you copy and paste the link into your browser.
http://www.rns-pdf.londonstockexchange.com/rns/5848S_1-2021-3-17.pdf
If you have any difficulties in opening the link, please contact Samantha Hawkins at RSM Restructuring Advisory LLP by e-mail: Samantha.Hawkins@rsmuk.com.
Dated: 17 March 2021
This notice is given by
Bruce Alexander Mackay
RSM Restructuring Advisory LLP
as Joint Liquidator of LB GP No.1 Ltd
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novartis Pharma AG19.10.2025 16:30:00 CEST | Press release
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom